Semaglutide, a benchmark product in the GLP-1 (glucagon-like peptide-1) receptor agonist field, has long held a core position in the global market for blood sugar-lowering and weight-loss drugs due to its dual core efficacy in lowering blood sugar and reducing weight. It has consistently ranked among the top blockbuster drugs globally for many years, with global sales exceeding $36 billion in 2025. This star drug, developed by Novo Nordisk, has long enjoyed market benefits solely through its robust patent barriers. However, the global patent expiration cycle starting in 2026 will completely disrupt this market monopoly, leading to a massive influx of generic drugs entering the market and reshaping the rules of competition in the global GLP-1 market. This has become one of the most watched industry transformation events in the pharmaceutical industry in recent years.
I. Global Tiered Patent Expiration Pattern: Core Patents First, Barriers Extended Layer by Layer
While the market generally perceives a concentrated expiration of semaglutide patents, this is actually a tiered, regionally differentiated process. Novo Nordisk has maximized the extension of its market exclusivity period by constructing a robust "patent jungle" system, avoiding the precipitous competition caused by the expiration of a single patent. Its patent system is divided into four main sections: core compound patents, formulation patents, drug delivery device patents, and indication patents, with significant differences in protection periods across different regions.
From the perspective of core compound patents, this is the core barrier to entry for generic drugs. The basic compound patents for semaglutide in emerging markets such as China, Canada, India, and Brazil are expiring in 2026. Specifically, the Chinese core patent CN101133082B expires on March 20, 2026, while the domestic drug data protection period extends to April 2027, creating a one-year buffer window. In the US market, the patent protection period for the core compound expires in December 2031, while in the EU, the basic patent expires in March 2032. Combined with the EU's Supplemental Patent Certificate (SPC) extension policy of up to five years, the patent exclusivity period in the core markets of Europe and the US can extend to 2035-2037. In the Japanese market, the core patent expires in June 2031.
Beyond the core patents, Novo Nordisk's more than 220 global derivative patents constitute a long-term competitive barrier, covering niche areas such as special formulations, dosage forms, injection devices, and oral formulation processes. The patent protection period generally extends to 2032-2033. This has led to a differentiated pace of generic drug launches globally: injectable generics are expected to be approved for launch in the European and American markets as early as 2031-2032, while oral generics may be available as early as around 2027. Meanwhile, emerging markets such as China and India, benefiting from the expiration of core patents, have become the first regions globally to see the full commercialization of semaglutide generics.
II. Global Generic Drug Application and Launch Status: Emerging Markets Lead the Charge
With the expiration of core patents, global pharmaceutical companies have rapidly launched their research and development and application strategies for generic semaglutide. Currently, over 60 pharmaceutical companies worldwide have entered the market, forming a competitive landscape centered on Chinese pharmaceutical companies and followed by many other countries. Emerging markets have been the first to enter the commercialization battleground.
The Chinese market is the core battleground for this wave of generic drugs. As of the first half of 2026, at least 16 domestic companies have advanced the research and development of generic semaglutide, with multiple products entering Phase III clinical trials, covering both injectable and oral formulations. Industry institutions predict that in 2026, the domestic market will see approximately five generic semaglutide drugs approved for launch, officially initiating competition between domestic generic drugs and original drugs. Compared to the high price of original drugs, domestic generic drugs, leveraging their cost advantages, will quickly lower prices after launch, covering primary healthcare and mass consumer markets.
India, a major global producer of generic drugs, has taken the lead in launching low-priced generic semaglutide, priced significantly lower than the original drug, thanks to its lenient approval policies and mature generic drug production system. These generics primarily supply emerging markets in South Asia, Southeast Asia, and Africa, rapidly capturing market share from the original drug's expansion into lower-tier markets. In contrast, mature markets in Europe and the US, constrained by derivative patents and biosimilar approval rules, have not yet seen large-scale generic drug launches. Currently, only a few pharmaceutical companies are conducting forward-looking research and development applications, and commercialization still awaits the complete removal of patent barriers.
It is important to clarify that semaglutide is a biological polypeptide drug, not a small molecule chemical drug, and the approval standards for its generic form vary globally. China, the US, and the EU all classify it as a biosimilar, requiring complete clinical trials and consistency evaluations, with stringent approval processes. Meanwhile, some emerging markets have relatively lenient approval standards, lowering the barriers to entry for generic drugs and further intensifying competition in the global market.
III. Industry-wide Market Transformation Brought About by Generic Drugs
1. Significant Price Decline and Rapid Increase in Market Penetration
The original semaglutide has long suffered from high pricing. Whether as a prescription drug for diabetes or a consumer drug for weight loss, the high price has limited market penetration. With the entry of generic drugs, the market price system has been completely restructured. The price of domestically produced generic drugs is expected to be only 30%-50% of the original drug, with even lower prices for overseas generics from India and other countries. This price reduction directly drives a surge in market demand. Diabetic and obese patients who previously forwent treatment due to cost are now accepting standardized medication. The global semaglutide market will continue to grow, but the premium of the original drug will be significantly compressed, leading to a continuous downward shift in the industry's profit center.
2. Market Restructuring and Weakening of the Original Drug's Monopoly
Before the patent expired, Novo Nordisk held exclusive control over pricing power and market influence in the global GLP-1 market. With the mass launch of generic drugs, the market share of original drugs in emerging markets has been rapidly diverted. By 2026, the market share of original drugs in China and India had already shown a significant decline. For the industry, semaglutide is no longer Novo Nordisk's exclusive blockbuster product, but has become a general-purpose basic product in the GLP-1 market. Numerous generic drug companies are leveraging their cost and distribution advantages to carve up the market, shifting industry competition from "single-product monopoly" to "large-scale, homogeneous competition."
3. The competitive landscape is evolving, with differentiated innovation becoming a core trend. The low barriers to entry for generic semaglutide in standard dosage forms and doses will quickly lead to price wars and continuously squeeze industry profits. Against this backdrop, global pharmaceutical companies are gradually shifting their R&D focus from simple generics to differentiated innovation. On the one hand, companies are focusing on niche areas such as long-acting formulations, combination formulations, and improved dosage forms to avoid low-end price competition; on the other hand, leading pharmaceutical companies are beginning to develop new target GLP-1 drugs and dual/multi-target agonists to replace traditional semaglutide products. Simultaneously, Novo Nordisk is accelerating the iteration of new products, consolidating its high-end market share through technological upgrades, forcing the entire GLP-1 market to shift from generic-driven to innovation-driven growth.
IV. Original Drug Manufacturer's Response Strategies and Long-Term Industry Trends
Faced with the impact of generic drugs, Novo Nordisk did not passively accept market loss, but instead hedged against patent expiration risks through multiple strategies. First, it initiated early price adjustments, lowering the listed price of its original drug in multiple global markets starting in 2027 to narrow the price gap with generic drugs and retain its core consumer base. Second, it built a growth curve based on subsequent iterative products, using next-generation long-acting GLP-1 drugs and dual-target drugs to capture existing market share. Third, it delayed the large-scale launch of generic drugs in some regions through patent litigation and intellectual property rights protection, safeguarding the interests of the existing market.
From a long-term industry development perspective, the expiration of the semaglutide patent is not the end of the industry's growth potential, but rather a turning point for the industry's standardization and popularization. In the short term, 2026-2030 will be a golden period for the global development of generic semaglutide. The widespread availability of low-priced drugs will rapidly open up the global market for weight loss and blood sugar-lowering drugs, leading to continuous market expansion. In the long term, competition among homogeneous generic drugs will eventually reach saturation, and only companies with advantages in dosage form innovation, target innovation, and commercial distribution channels will be able to maintain their market dominance. For domestic pharmaceutical companies, the launch of generic semaglutide presents both an opportunity to enter the high-end biopharmaceutical market and a crucial opportunity to force companies to move beyond simple imitation and delve into original innovation.
Shaanxi Lv Ke Chun Yuan Biotechnology Co., Ltd
Our address
Huaxia Yue World, Weibin District, Baoji City, Shaanxi Province
Phone Number
+86-13571783771
